Gene Therapy Trial for Wet AMD Enrolls Early Promising Long-Lasting Vision Protection
A Phase 3 trial testing a single-injection gene therapy for wet AMD finished enrollment 4 months early, with results due in 2027.
Summary
Wet age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, typically requiring frequent eye injections. 4DMT's Phase 3 trial of 4D-150 — a gene therapy designed to deliver anti-VEGF treatment continuously for years from a single injection — has completed global enrollment ahead of schedule. The trial compares 4D-150 against the standard-of-care drug aflibercept, with the main goal of showing equal effectiveness while reducing injection frequency. Early enrollment completion signals strong investigator and patient interest. If successful, this approach could dramatically cut treatment burden for millions of older adults managing AMD, replacing monthly clinic visits with rare or one-time procedures. Results are expected in 2027.
Detailed Summary
Wet age-related macular degeneration is one of the most common causes of severe vision loss in people over 60, and managing it typically demands repeated injections into the eye — sometimes every four to eight weeks for the rest of a patient's life. This treatment burden is a major barrier to adherence and quality of life, and it represents a significant cost to healthcare systems globally.
4D Molecular Therapeutics (4DMT) has now completed enrollment in 4FRONT-2, its second Phase 3 clinical trial of 4D-150, a gene therapy candidate designed to address this problem. The trial finished enrolling more than 500 patients roughly four months ahead of schedule, a notable sign of strong interest from clinical sites and patients alike.
4D-150 uses an engineered AAV viral vector to deliver genetic instructions directly into the eye, enabling retinal cells to continuously produce their own anti-VEGF proteins — the same class of biologics currently given as repeated injections. The goal is sustained, multi-year therapeutic effect from a single treatment. In the trial, 4D-150 is being compared head-to-head against aflibercept 2 mg given every eight weeks, with success defined as equivalent visual acuity outcomes and fewer required injections over 52 weeks.
Topline results from the companion 4FRONT-1 trial are expected in the first half of 2027, with 4FRONT-2 data following in the second half of 2027. If both trials succeed, 4D-150 could represent a paradigm shift in AMD care — transforming a chronic, high-frequency treatment regimen into a rare or once-only procedure.
For older adults concerned about preserving vision and independence into later life, this technology warrants close attention. Caveats remain: the trials are still ongoing, and long-term safety and durability data are not yet available.
Key Findings
- 4FRONT-2 enrolled 500+ patients roughly 4 months ahead of schedule, signaling high trial demand.
- 4D-150 uses AAV gene therapy to enable the eye to produce its own anti-VEGF proteins continuously.
- Primary endpoint compares visual acuity outcomes against standard aflibercept injections at 52 weeks.
- Key secondary endpoint measures reduction in total injection burden — a major quality-of-life factor.
- Phase 3 topline results expected in 2027, potentially setting stage for regulatory submission.
Methodology
This is a news report summarizing a company press announcement about Phase 3 trial enrollment completion. The source, Longevity.Technology, is a credible health and longevity media outlet. Evidence is based on company-reported enrollment data, not yet peer-reviewed clinical outcomes.
Study Limitations
Results are not yet available; all claims about efficacy and durability are based on trial design and company projections. Long-term safety of intravitreal AAV gene therapy in humans remains under study. Independent peer-reviewed data should be awaited before clinical conclusions are drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: